INmune Bio Inc (INMB)
11.18
-0.02
(-0.22%)
USD |
NASDAQ |
May 07, 16:00
11.18
0.00 (0.00%)
After-Hours: 18:43
INmune Bio Cash from Financing (TTM): -4.225M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -4.225M |
September 30, 2023 | -1.725M |
June 30, 2023 | 0.00 |
March 31, 2023 | 0.00 |
December 31, 2022 | 0.729M |
September 30, 2022 | 0.729M |
June 30, 2022 | 53.67M |
March 31, 2022 | 68.62M |
December 31, 2021 | 96.36M |
September 30, 2021 | 96.36M |
June 30, 2021 | 66.66M |
Date | Value |
---|---|
March 31, 2021 | 52.37M |
December 31, 2020 | 23.90M |
September 30, 2020 | 23.90M |
June 30, 2020 | 0.655M |
March 31, 2020 | 4.949M |
December 31, 2019 | 12.21M |
September 30, 2019 | 12.21M |
June 30, 2019 | 12.21M |
March 31, 2019 | 7.251M |
December 31, 2018 | 0.90M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-4.225M
Minimum
Dec 2023
96.36M
Maximum
Sep 2021
27.35M
Average
12.21M
Median
Jun 2019
Cash from Financing (TTM) Benchmarks
Biomarin Pharmaceutical Inc | -20.78M |
Sarepta Therapeutics Inc | 45.35M |
Dare Bioscience Inc | 15.64M |
Zevra Therapeutics Inc | 28.46M |
Kodiak Sciences Inc | 0.031M |